Evolutionary Genomics (FNAM) 10-Q 8 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 08, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	000-54129
Entity Registrant Name	EVOLUTIONARY GENOMICS, INC.
Entity Central Index Key	0000884363
Entity Tax Identification Number	26-4369698
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	4220 Morning Star Drive
Entity Address, City or Town	Castle Rock
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80108
City Area Code	(720)
Local Phone Number	900-8666
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		6,655,232

Condensed and Consolidated Bala

Condensed and Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash	$ 897,779	$ 214,009
Prepaid expenses	26,457	41,792
Total current assets	924,236	255,801
Non-current assets
Property and equipment, net	11,327	18,698
Intangible assets, net	2,154,217	2,657,592
Total non-current assets	2,165,544	2,676,290
Total assets	3,089,780	2,932,091
Current liabilities
Accounts payable and accrued expenses	93,844	18,866
Total current liabilities	93,844	18,866
Long-term liabilities
Notes payable	3,743,747	3,743,747
Total liabilities	3,837,591	3,762,613
Commitments and contingencies
Total preferred stock subject to possible redemption	4,023,598	3,569,594
Stockholders' deficit
Preferred Stock - accrued dividends	1,672,822	1,521,796
Common Stock, $0.001 par value; 780,000,000 shares authorized, 6,655,232 and 5,881,898 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	6,655	5,882
Additional paid-in capital	12,482,548	11,949,702
Accumulated deficit	(18,933,434)	(17,877,496)
Total stockholders' deficit	(4,771,409)	(4,400,116)
Total liabilities and stockholders' deficit	3,089,780	2,932,091
Series A 1 Convertible Preferred Stock [Member]
Long-term liabilities
Total preferred stock subject to possible redemption	3,029,579	3,029,579
Series A 2 Convertible Preferred Stock [Member]
Long-term liabilities
Total preferred stock subject to possible redemption	$ 994,019	$ 540,015

Condensed and Consolidated Ba_2

Condensed and Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Preferred stock, par or stated value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	780,000,000	780,000,000
Common stock, shares issued	6,655,232	5,881,898
Common stock, shares outstanding	6,655,232	5,881,898
Series A 1 Convertible Preferred Stock [Member]
Preferred stock, par or stated value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares issued	577,063	577,063
Preferred stock, shares outstanding	577,063	577,063
Preferred stock, liquidation preference, value	$ 4,557,483
Series A 2 Convertible Preferred Stock [Member]
Preferred stock, par or stated value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	200,000	200,000
Preferred stock, shares issued	189,337	102,860
Preferred stock, shares outstanding	189,337	102,860
Preferred stock, liquidation preference, value	$ 1,138,937

Condensed and Consolidated Stat

Condensed and Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenue
Operating expenses
Research and development	106,178	136,199	205,267	233,014
Salaries and benefits	115,686	92,429	209,645	184,859
General and administrative	309,568	325,079	641,464	649,684
Total operating expenses	531,432	553,707	1,056,376	1,067,557
Operating loss	(531,432)	(553,707)	(1,056,376)	(1,067,557)
Other income:
Investment income	359	6	438	114
Total other income	359	6	438	114
Loss before income taxes	(531,073)	(553,701)	(1,055,938)	(1,067,443)
Income taxes
Net loss	(531,073)	(553,701)	(1,055,938)	(1,067,443)
Preferred stock dividends	(80,251)	(71,392)	(151,026)	(142,784)
Net loss attributable to common stockholders	$ (611,324)	$ (625,093)	$ (1,206,964)	$ (1,210,227)
Net loss per common share, basic	$ (0.09)	$ (0.11)	$ (0.19)	$ (0.21)
Net loss per common share, diluted	$ (0.09)	$ (0.11)	$ (0.19)	$ (0.21)
Weighted average common shares outstanding, basic	6,631,935	5,881,898	6,258,988	5,881,898
Weighted average common shares outstanding, diluted	6,631,935	5,881,898	6,258,988	5,881,898

Condensed and Consolidated St_2

Condensed and Consolidated Statement of Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Preferred Dividend [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 5,882	$ 1,236,228	$ 12,015,552	$ (15,083,552)	$ (1,825,890)
Beginning balance, shares at Dec. 31, 2020	5,881,898
Stock compensation			54,930		54,930
Preferred stock dividends		71,392	(71,392)
Net loss				(513,742)	(513,742)
Ending balance, value at Mar. 31, 2021	$ 5,882	1,307,620	11,999,090	(15,597,294)	(2,284,702)
Ending balance, shares at Mar. 31, 2021	5,881,898
Stock compensation			54,929		54,929
Preferred stock dividends		71,392	(71,392)
Net loss				(553,701)	(553,701)
Ending balance, value at Jun. 30, 2021	$ 5,882	1,379,012	11,982,627	(16,150,995)	(2,783,474)
Ending balance, shares at Jun. 30, 2021	5,881,898
Beginning balance, value at Dec. 31, 2021	$ 5,882	1,521,796	11,949,702	(17,877,496)	(4,400,116)
Beginning balance, shares at Dec. 31, 2021	5,881,898
Common Stock issuance	$ 733		549,267		550,000
Common Stock issuance, shares	733,333
Stock compensation			56,459		56,459
Preferred stock dividends		70,775	(70,775)
Net loss				(524,865)	(524,865)
Ending balance, value at Mar. 31, 2022	$ 6,615	1,592,571	12,484,653	(18,402,361)	(4,318,522)
Ending balance, shares at Mar. 31, 2022	6,615,231
Beginning balance, value at Dec. 31, 2021	$ 5,882	1,521,796	11,949,702	(17,877,496)	(4,400,116)
Beginning balance, shares at Dec. 31, 2021	5,881,898
Ending balance, value at Jun. 30, 2022	$ 6,655	1,672,822	12,482,548	(18,933,434)	(4,771,409)
Ending balance, shares at Jun. 30, 2022	6,655,232
Beginning balance, value at Mar. 31, 2022	$ 6,615	1,592,571	12,484,653	(18,402,361)	(4,318,522)
Beginning balance, shares at Mar. 31, 2022	6,615,231
Option exercise	$ 40		(40)
Option exercise, shares	40,001
Stock compensation			78,186		78,186
Preferred stock dividends		80,251	(80,251)
Net loss				(531,073)	(531,073)
Ending balance, value at Jun. 30, 2022	$ 6,655	$ 1,672,822	$ 12,482,548	$ (18,933,434)	$ (4,771,409)
Ending balance, shares at Jun. 30, 2022	6,655,232

Condensed and Consolidated St_3

Condensed and Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (1,055,938)	$ (1,067,443)
Adjustments to reconcile net loss to net cash flows from operating activities
Depreciation and amortization	510,746	519,408
Stock-based compensation	134,645	109,859
Changes in operating assets and liabilities:
Prepaid expenses	15,335	20,464
Accounts payable and accrued expenses	74,978	126,069
Cash flows from operating activities	(320,234)	(291,643)
Cash flows from investing activities:
Cash flows from investing activities
Cash flows from financing activities:
Proceeds from issuance of Common Stock	550,000
Proceeds from issuance of Preferred Stock	454,004
Proceeds from issuance of notes payable		76,395
Cash flows from financing activities	1,004,004	76,395
Net change in cash	683,770	(215,248)
Cash, beginning of period	214,009	215,836
Cash, end of period	897,779	588
Supplemental cash flow information
Preferred stock dividend accrual	$ 151,026	$ 142,784

Business Activity

Business Activity	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Business Activity	Note 1: Business Activity Evolutionary Genomics, Inc. (the “Company,” “We,” or “Our”) has developed a technology platform, the Adapted Traits Platform (“ATP”), to identify commercially valuable genes that control important traits in animals and plants. We are using the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. Our platform identifies key genes that have changed successfully to impart new or improved traits. In the past, the Company performed research on behalf of governmental organizations, non-profit foundations and commercial entities and received revenue from grants and commercial research contracts. We have not received any revenue from these grant arrangements since early 2020. The Company now focuses on research projects that may lead to long-term licensing arrangements with agricultural seed companies and crop producers as with our soybean and banana projects. These projects take several years to develop and successful commercialization may take many years to produce license royalty payments. Our banana project, in cooperation with Dole Food Company is an example that has resulted in notes payable funding for the development phase of our banana genes and, if successful, may result in a long-term royalty bearing license once the development phase is complete. During 2014, the Company purchased 75.16% of the outstanding stock of Fona, Inc., (“Fona”) a public shell company. Since Fona was a public shell company which did not constitute a business and the purchase was done in contemplation of a reverse merger, the Company accounted for the payment as a distribution to Fona shareholders. The Company also entered into an Agreement and Plan of Merger (the “Merger”), which was consummated on October 19, 2015. As a result of the Merger, Evolutionary Genomics, Inc. became a wholly owned subsidiary of Fona. For accounting purposes, the merger was treated as a reverse acquisition with Evolutionary Genomics, Inc. as the acquirer and Fona as the acquired party. Subsequent to the Merger, Fona was renamed Evolutionary Genomics, Inc. and our subsidiary was renamed from Evolutionary Genomics, Inc. to EG Crop Science, Inc.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies	Note 2: Summary of Significant Accounting Policies Basis of presentation The condensed consolidated balance sheet as of December 31, 2021, has been derived from the Company’s audited consolidated financial statements. The unaudited interim financial statements should be read in conjunction with the Company’s 2021 Form 10-K, which contains the Company’s audited financial statements and notes thereto, together with the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2021. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnote disclosures necessary for a comprehensive presentation of financial position, results of operations, and cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the six months and three months ended June 30, 2022 are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the fiscal year ending December 31, 2022. Principals of Consolidation Use of Estimates Cash Property and Equipment Long-Lived Assets Intangible Assets No Income Taxes Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits. Stock-Based Compensation The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement. Research and Development Net Loss Per Common Share 766,400 1,028,333 679,923 1,081,667

New Accounting Standards

New Accounting Standards	6 Months Ended
	Jun. 30, 2022
Accounting Changes and Error Corrections [Abstract]
New Accounting Standards	Note 3: New Accounting Standards Recently Issued Accounting Standards In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments,” which requires entities to estimate all expected credit losses for certain types of financial instruments, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The updated guidance also expands the disclosure requirements to enable users of financial statements to understand the entity’s assumptions, models and methods for estimating expected credit losses over the entire contractual term of the instrument from the date of initial recognition of that instrument. This guidance is effective for fiscal years beginning after December 15, 2022, including interim periods within that reporting period and is not expected to have an impact on the Company’s consolidated financial statements.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 4: Property and Equipment Property and equipment is comprised of the following: Schedule of Property and Equipment June 30, December 31, 2022 2021 Equipment $ 432,499 $ 432,499 Software 63,179 63,179 Furniture and fixtures 7,987 7,987 503,665 503,665 Accumulated depreciation (492,338 ) (484,967 ) Property and equipment, net $ 11,327 $ 18,698 7,371 16,033 Depreciation expense for the three months ended June 30, 2022 and 2021 was $ 3,686 8,017

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 5: Intangible Assets Intangible assets are comprised of the following: Schedule of Intangible Assets June 30, December 31, 2022 2021 Acquired research in progress - definite lived $ 4,016,596 $ 4,016,596 Patents 52,045 52,045 Accumulated amortization (1,914,424 ) (1,411,049 ) Intangible assets, net $ 2,154,217 $ 2,657,592 The Company expects to recognize amortization expense related to its acquired research in progress and patents according to the following: Schedule of Intangible Assets Amortization Year Ending Amortization December 31, 2022 $ 503,376 December 31, 2023 1,006,751 December 31, 2024 638,105 December 31, 2025 2,602 December 31, 2026 2,602 Thereafter 781 Total $ 2,154,217 503,375 Amortization expense for the acquired research in progress and patents during the three months ended June 30, 2022 and 2021 was $ 251,688 In its merger completed on October 19, 2015, the Company acquired research in progress. The value of the acquired research in progress was based upon several factors including, evaluation of other intangible assets, the purchase price, estimated future cash flows, and the amounts expended on the research to date. The research in progress was the identification and validation of genes to provide pest and disease resistance to plants. With the banana development project contract in place and the expected marketing of our soybean genes in fall-2022, the Company placed this asset in service on August 19, 2020. Additional costs to complete the soybean research are expected to be approximately $ 33,000

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	Note 6: Notes Payable Small Business Administration (“SBA”) Paycheck Protection Program (“PPP”): 76,395 SBA Economic Injury Disaster Loan: 150,000 7,000 50,000 3.75 1,020 13,510 Dole Food Company: On August 19, 2020, the Company entered into a Development and Commercialization Agreement (“DCA”) with Dole Food Company (“Dole”) for the development of our banana genes. The DCA provides for payments from Dole to the Company of $ 800,000 800,000 250,000 250,000 2,200,000 2,159,719 750,000 The DCA also specifies that the Company will execute notes payable to Dole for the funding that Dole is providing up to $ 5,050,000 800,000 800,000 1,295,831 647,916

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stockholders’ Equity	Note 7: Stockholders’ Equity The Amended and Restated Certificate of Incorporation of the Company dated October 19, 2015 authorized the issuance of 800,000,000 780,000,000 0.001 20,000,000 0.001 600,000 200,000 733,333 550,000 86,477 454,004 Liquidation 5.25 Conversion Optional Redemption; Sinking Fund Account: 5.25 Dividends 8 1,672,822 Voting

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 8: Stock-Based Compensation 1,400,000 134,645 109,859 78,186 54,929 133,333 0 Management has valued the options at their date of grant utilizing the Black-Scholes option pricing model. Volatility of the underlying common shares was determined based on the historical volatility for the Company’s for a term consistent with the expected life of the options. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options on the date of the grant. Due to the lack of sufficient historical activity, the expected term of the options was estimated using the formula set forth in Securities and Exchange Commission SAB 107. The fair value of the share option awards was estimated using the Black-Scholes method based on the following weighted-average assumptions: Schedule Weighted Average Assumptions Volatility 154 Expected Term 5.5 Dividend Rate 0 Risk Free Rate 2.56 The following table summarizes the status of the Company’s aggregate stock options granted: Schedule of Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Term (Years) Total Intrinsic Value Balance, January 1, 2021 1,081,667 $ 1.74 6.67 Granted — — — Exercised — — — Cancelled — — — Balance, December 31, 2021 1,081,667 $ 1.74 5.67 Balance, January 1, 2022 1,081,667 $ 1.74 5.67 Granted 133,333 $ 0.83 9.73 Exercised (186,667 ) $ 0.55 — Cancelled — — — Balance, June 30, 2022 1,028,333 $ 1.84 6.73 $ — Exercisable at June 30, 2022 681,665 $ 2.13 5.95 $ — During each of the six months and three months ended June 30, 2022 and 2021, options for 0 144,111 During the six months ended June 30, 2022, options for 186,667 0.55 40,001

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9: Commitments and Contingencies Officer Indemnification Lease Commitments 2,378 11,890 14,267 Royalty 262,400 393,600 Other Commitments: 2,159,719 2 143,124 85,874

Related Parties and Transaction

Related Parties and Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Parties and Transactions	Note 10: Related Parties and Transactions Steve B. Warnecke: 1,841,374 24.81

Concentrations

Concentrations	6 Months Ended
	Jun. 30, 2022
Risks and Uncertainties [Abstract]
Concentrations	Note 11: Concentrations Considerations of Credit Risk

Liquidity

Liquidity	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity	Note 12: Liquidity As of June 30, 2022, the Company had $ 897,779 840,000

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation The condensed consolidated balance sheet as of December 31, 2021, has been derived from the Company’s audited consolidated financial statements. The unaudited interim financial statements should be read in conjunction with the Company’s 2021 Form 10-K, which contains the Company’s audited financial statements and notes thereto, together with the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2021. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnote disclosures necessary for a comprehensive presentation of financial position, results of operations, and cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the six months and three months ended June 30, 2022 are not necessarily indicative of the financial condition and results of operations that may be expected for any future interim period or for the fiscal year ending December 31, 2022.
Principals of Consolidation	Principals of Consolidation
Use of Estimates	Use of Estimates
Cash	Cash
Property and Equipment	Property and Equipment
Long-Lived Assets	Long-Lived Assets
Intangible Assets	Intangible Assets No
Income Taxes	Income Taxes Under the Income Tax topic of the ASC, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company has no accruals for uncertain tax benefits.
Stock-Based Compensation	Stock-Based Compensation The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services received follows the provisions of ASC Topic 718. Accordingly, the measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete. In the case of equity instruments issued to consultants, the fair value of the equity instrument is recognized over the term of the consulting agreement.
Research and Development	Research and Development
Net Loss Per Common Share	Net Loss Per Common Share 766,400 1,028,333 679,923 1,081,667

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Schedule of Property and Equipment June 30, December 31, 2022 2021 Equipment $ 432,499 $ 432,499 Software 63,179 63,179 Furniture and fixtures 7,987 7,987 503,665 503,665 Accumulated depreciation (492,338 ) (484,967 ) Property and equipment, net $ 11,327 $ 18,698

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Schedule of Intangible Assets June 30, December 31, 2022 2021 Acquired research in progress - definite lived $ 4,016,596 $ 4,016,596 Patents 52,045 52,045 Accumulated amortization (1,914,424 ) (1,411,049 ) Intangible assets, net $ 2,154,217 $ 2,657,592
Schedule of Intangible Assets Amortization	Schedule of Intangible Assets Amortization Year Ending Amortization December 31, 2022 $ 503,376 December 31, 2023 1,006,751 December 31, 2024 638,105 December 31, 2025 2,602 December 31, 2026 2,602 Thereafter 781 Total $ 2,154,217

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule Weighted Average Assumptions	Schedule Weighted Average Assumptions Volatility 154 Expected Term 5.5 Dividend Rate 0 Risk Free Rate 2.56
Schedule of Stock Option Activity	Schedule of Stock Option Activity Number of Options Weighted Average Exercise Price Weighted Average Remaining Term (Years) Total Intrinsic Value Balance, January 1, 2021 1,081,667 $ 1.74 6.67 Granted — — — Exercised — — — Cancelled — — — Balance, December 31, 2021 1,081,667 $ 1.74 5.67 Balance, January 1, 2022 1,081,667 $ 1.74 5.67 Granted 133,333 $ 0.83 9.73 Exercised (186,667 ) $ 0.55 — Cancelled — — — Balance, June 30, 2022 1,028,333 $ 1.84 6.73 $ — Exercisable at June 30, 2022 681,665 $ 2.13 5.95 $ —

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Asset impairment charges	$ 0	$ 0	$ 0	$ 0
Options Held [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	1,028,333	1,081,667	1,028,333	1,081,667
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	766,400	679,923	766,400	679,923

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 503,665	$ 503,665
Accumulated depreciation	(492,338)	(484,967)
Property and equipment, net	11,327	18,698
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	432,499	432,499
Software and Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	63,179	63,179
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 7,987	$ 7,987

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 3,686	$ 8,017	$ 7,371	$ 16,033

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Intangible assets, accumulated amortization	$ (1,914,424)	$ (1,411,049)
Intangible assets, net	2,154,217	2,657,592
In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	4,016,596	4,016,596
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 52,045	$ 52,045

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
December 31, 2022	$ 503,376
December 31, 2023	1,006,751
December 31, 2024	638,105
December 31, 2025	2,602
December 31, 2026	2,602
Thereafter	781
Total	$ 2,154,217	$ 2,657,592

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization	$ 251,688	$ 251,688	$ 503,375	$ 503,375
In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Additional expected costs to complete research		$ 33,000		$ 33,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)			1 Months Ended		6 Months Ended
	Jul. 14, 2021	Jun. 05, 2020	Jul. 20, 2021	Feb. 22, 2021	Jun. 30, 2022	Jun. 30, 2021	Sep. 29, 2021	Jul. 28, 2021	Dec. 29, 2020	Aug. 26, 2020	Aug. 19, 2020
Short-Term Debt [Line Items]
Proceeds						$ 76,395
S B A Paycheck Protection Program [Member]
Short-Term Debt [Line Items]
Proceeds				$ 76,395
E I D L Program [Member]
Short-Term Debt [Line Items]
Proceeds	$ 50,000	$ 150,000
Interest rate		3.75%
Monthly payment		$ 1,020
Accrued interest					$ 13,510
Economic Injury Disaster Loan [Member]
Short-Term Debt [Line Items]
Proceeds			$ 7,000
D C A Dole [Member]
Short-Term Debt [Line Items]
Payment upon execution											$ 800,000
Payment twelve-month anniversary											800,000
Payment thirty six month anniversary											250,000
Payment forty eight month anniversary											250,000
Reimbursement of costs											2,200,000
Expected field trial costs											750,000
Notes payable for dole funding											5,050,000
Payment upon receipt							$ 647,916	$ 800,000	$ 1,295,831	$ 800,000
Research Agreement University Of Wisconsin Madison [Member]
Short-Term Debt [Line Items]
Expected payments University of Wisconsin-Madison											$ 2,159,719

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
	Mar. 31, 2022	Jun. 30, 2022	Dec. 31, 2021	Oct. 19, 2015
Class of Stock [Line Items]
Capital stock, authorized shares				800,000,000
Common stock, authorized shares		780,000,000	780,000,000	780,000,000
Common stock, par value		$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized shares		20,000,000	20,000,000	20,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001	$ 0.001
Proceeds	$ 550,000
Preferred stock liquidation, stated value per share		$ 5.25	$ 5.25
Preferred Stock - accrued dividends		$ 1,672,822	$ 1,521,796
Series A 2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Dividend rate		8%
Series A 1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Dividend rate		8%
Series A 1 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, authorized shares		600,000	600,000	600,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Series A 2 Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, authorized shares		200,000	200,000	200,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Shares issued		86,477
Proceeds		$ 454,004
Common Stock [Member]
Class of Stock [Line Items]
Shares issued		733,333
Proceeds		$ 550,000

Stock-Based Compensation (Detai

Stock-Based Compensation (Details)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Volatility	154%
Expected Term	5 years 6 months
Dividend Rate	0%
Risk Free Rate	2.56%

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details 1) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]
Number of Options, Beginning	1,081,667	1,081,667
Weighted Average Exercise Price, Beginning	$ 1.74	$ 1.74
Weighted Average Remaining Term (Years), Outstanding	6 years 8 months 23 days	5 years 8 months 1 day	6 years 8 months 1 day
Number of Options, Granted	133,333
Weighted Average Exercise Price, Granted	$ 0.83
Weighted Average Remaining Term (Years), Granted	9 years 8 months 23 days
Number of Options, Exercised	(186,667)
Weighted Average Exercise Price, Exercised	$ 0.55
Number of Options, Cancelled
Weighted Average Exercise Price, Cancelled
Number of Options, Ending	1,028,333	1,081,667	1,081,667
Weighted Average Exercise Price, Ending	$ 1.84	$ 1.74	$ 1.74
Number of Options, Exercisable	681,665
Weighted Average Exercise Price, Exercisable	$ 2.13
Weighted Average Remaining Term (Years), Exercisable	5 years 11 months 12 days
Exercisable, Intrinsic value

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares reserved for issuance under 2015 Stock Incentive Plan	1,400,000		1,400,000
Compensation costs for stock options	$ 78,186	$ 54,929	$ 134,645	$ 109,859
Stock options granted during period			133,333	0
Number of shares vested during the period	0	0	0	0
Unrecognized compensation cost related to share-based compensation arrangements	$ 144,111		$ 144,111
Stock option, shares			186,667
Exercise per share			$ 0.55
Issuance of shares	40,001		40,001
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option, shares			186,667
Exercise per share			$ 0.55

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended
	Apr. 18, 2022	Sep. 18, 2020	Jun. 30, 2022	Jun. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Monthly rent payment			$ 2,378
Rent expense			11,890	$ 14,267
Total amount of grant revenue recognized to date			262,400
Total possible future royalties owed			393,600
Other expenses	$ 143,124
Payment to contract amount			$ 85,874
Standard Research Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments for royalties		$ 2,159,719
Term		2 years

Related Parties and Transacti_2

Related Parties and Transactions (Details Narrative) - Chief Executive Officer [Member]	Jun. 30, 2022 shares
Related Party Transaction [Line Items]
Number of common stock shares outstanding owned by related party	1,841,374
Percentage of common stock shares outstanding owned by related party	24.81%

Liquidity (Details Narrative)

Liquidity (Details Narrative)	Jun. 30, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating cash	$ 897,779
Cash	$ 840,000